Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00414635 · ClinicalTrials.gov registry record · Phase 4

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

A Phase 4 study, sponsored by Community Research Initiative of New England.

Completed
Registry status
Phase 4
Development phase
60
Enrollment target

NCT00414635: Completed Phase 4 study, sponsored by Community Research Initiative of New England.

NCT00414635 is a Phase 4 study that has completed, run by Community Research Initiative of New England. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00414635, a Phase 4 study, has completed, sponsored by Community Research Initiative of New England.

COMPLETED
Registry status
Phase 4
Development phase
60 participants
Enrollment target

Study Summary

For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week compared with seven days of the week.

Interventions

  • DRUG Intermitent Dosing

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-08
Est. Completion 2009-12
Phase Phase 4

What the Registry Record Tells You About NCT00414635

The ClinicalTrials.gov registry entry for NCT00414635 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Community Research Initiative of New England, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Intermitent Dosing is the first listed.

NCT00414635 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00414635 about?

NCT00414635 is a clinical study titled "FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment". For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week compared with seven days of the week.

What is the current status of trial NCT00414635?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2006-08. Estimated completion is 2009-12.

What interventions are being tested in trial NCT00414635?

The interventions under investigation include: Intermitent Dosing (DRUG).

Who is sponsoring clinical trial NCT00414635?

This trial is sponsored by Community Research Initiative of New England, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.